Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

31
Oakmark Fund: Second Quarter 2018

2018-07-13 seekingalpha
Average Annual Total Returns (06/30/18) Since Inception (08/05/91) 12.84% 10–year 12.48% 5–year 13.07% 1–year 13.46% 3–month 2.13% Gross Expense Ratio as of 09/30/17 was 0.90% Net Expense Ratio as of 09/30/17 was 0.86%
MGM APC FB BMYMP AAL ADP MA NFLX HOG IT V AFL ADPVV AAPL HLT AEUA BMY

0
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

2018-07-11 globenewswire
COPENHAGEN, Denmark, July 11, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO®), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC).
BVNKF BMYMP BMY BVNRY

73
SANUWAVE Signs Joint Venture Partnership with Tarbaca for 3 Countries in Central America

2018-06-26 globenewswire
SUWANEE, GA, June 26, 2018 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) is excited to announce the execution of a binding term sheet for a Joint Venture (JV) with Tarbaca Lightning, the distribution company of Latin America Pharma Supply Inc. The JV will cover Costa Rica, Panama, and El Salvador. It is expected that the JV will receive their initial devices in the second half of 2018 and begin generating revenue shortly thereafter.
SNWW BMYMP SNWV BMY

123
AGTC Announces Expansion of Clinical and Regulatory Leadership Teams

2018-06-14 globenewswire
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs
AGTC REGN BMYMP BMY

351
This One Study Could Radically Change The Cancer Immunotherapy Market

2018-06-07 seekingalpha
The cause is speculated to be that antibiotics clear the gut of bacteria, which decreases the amount of circulating immune cells, which in turn lessens the effect of immunotherapy.
SGEN MRK TSRO AMGN BMYMP ADXS BLUE CELG BLUE SNDX BMY

77
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting

2018-06-04 globenewswire
– PD-L1 Targeting Probody CX-072 Well Tolerated and Shows Antitumor Activity as Monotherapy and in Combination with Ipilimumab –
BMYMP CTMX BMY

76
CytomX to Present at the Jefferies 2018 Healthcare Conference

2018-05-31 globenewswire
SOUTH SAN FRANCISCO, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Jefferies 2018 Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on June 7, 2018, at 2:00 p.
BMYMP CTMX BMY

523
Your Daily Pharma Scoop: ACRX NDA Accepted, BioMarin Gets Approval, Genmab Fails Study

2018-05-27 seekingalpha
AcelRX (NASDAQ:ACRX), as I have repeatedly noted, is a trader’s dream stock. It moves from plateau to plateau, but while in each plateau, it keeps itself extremely range-bound - therefore predictable. That predictability was shattered only once - if you look at its one-year chart - in October last. This happened when the stock suddenly jumped almost overnight, from around $3 to above $5, on the basis of a PDUFA date in October 2017.
BMYMP RVNC IDRAW DERM VSTM TEVA TEVVF AMRN ACRX BMRN REPH TEVJF IDRA ABBV TNXP BMY ABBV

76
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic

2018-05-22 globenewswire
SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for CX-2029, a first-in-class CD71-directed Probody™ drug conjugate being co-developed by CytomX and its partner AbbVie.
BMYMP CTMX BMY

72
SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

2018-05-17 globenewswire
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) today announced that data from the Company’s ongoing Phase 1/2 study of galinpepimut-S (GPS) in combination with Bristol Myers Squibb’s nivolumab in patients with Wilms Tumor 1 + ovarian cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1 - 5, 2018 in Chicago, Illinois.
BMYMP BMY

76
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting

2018-05-16 globenewswire
SOUTH SAN FRANCISCO, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
BMYMP CTMX BMY

156
Eli Lilly Had Good Reason To Spend $1.6B On Armo

2018-05-16 seekingalpha
Last week Eli Lilly (LLY) spent $1.6 billion on to acquire Armo BioSciences (ARMO) at a 66% premium to its previous closing price.
SGEN MRK ARMO AMGN BMYMP INCY BMY SNDX

307
5 Best-Performing Health Care Mutual Funds of Q1

2018-05-02 zacks
In the first quarter, among the three major U.S. indexes, both the Dow and the S&P 500 finished in the red. Although, healthcare was one such S&P 500 sector that registered declines in the first quarter, it surpassed all the other sectors to witness highest venture capital funding.
DLHIX WFCNP WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP BSX WFC.PRO ALXN WFC.PRN CELG WFC.PRY WFC.PRX WFC.PRW BMY WFC.PRV WFC WFC.WS AMGN BMYMP CELGZ MPSYY FSPHX MDT FBDIX MPSYF UNH

204
Ovid Therapeutics: Beaten Down IPO With Upcoming 2018 Catalysts

2018-05-01 seekingalpha
Data from the phase 2 STARS trial for OV101 in Angelman’s syndrome is expected in Q3, 2018.
MRNS SAGE NITE BMYMP OVID ZYNE GWP BMY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 110122908